Regeneron Pharmaceuticals, Inc.
REGN
$718.16
-$26.67-3.58%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 13.69B | 13.30B | 12.92B | 12.56B | 12.58B |
| Total Other Revenue | 515.00M | 548.10M | 572.20M | 537.00M | 536.10M |
| Total Revenue | 14.20B | 13.85B | 13.49B | 13.10B | 13.12B |
| Cost of Revenue | 6.02B | 5.74B | 5.49B | 5.40B | 5.28B |
| Gross Profit | 8.18B | 8.11B | 8.00B | 7.70B | 7.84B |
| SG&A Expenses | 2.95B | 2.90B | 2.83B | 2.72B | 2.63B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 29.90M | 29.40M | 28.90M | 13.70M | -2.10M |
| Total Operating Expenses | 10.09B | 9.75B | 9.42B | 9.11B | 8.88B |
| Operating Income | 4.12B | 4.10B | 4.07B | 3.99B | 4.23B |
| Income Before Tax | 4.78B | 4.97B | 4.59B | 4.04B | 4.20B |
| Income Tax Expenses | 367.30M | 314.90M | 265.50M | 184.20M | 245.70M |
| Earnings from Continuing Operations | 4.41K | 4.65K | 4.32K | 3.86K | 3.95K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 4.41B | 4.65B | 4.32B | 3.86B | 3.95B |
| EBIT | 4.12B | 4.10B | 4.07B | 3.99B | 4.23B |
| EBITDA | 4.60B | 4.57B | 4.52B | 4.42B | 4.65B |
| EPS Basic | 40.88 | 43.23 | 40.31 | 36.11 | 37.05 |
| Normalized Basic EPS | 27.81 | 27.40 | 27.05 | 26.28 | 27.24 |
| EPS Diluted | 38.29 | 40.41 | 37.76 | 33.85 | 34.75 |
| Normalized Diluted EPS | 26.06 | 25.61 | 25.35 | 24.64 | 25.56 |
| Average Basic Shares Outstanding | 431.60M | 430.60M | 428.80M | 427.70M | 427.00M |
| Average Diluted Shares Outstanding | 460.50M | 460.50M | 457.70M | 456.20M | 455.10M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
